Earnings Feed
Start Free
Nuvalent, Inc.·4

Mar 26, 4:30 PM ET

Balcom Alexandra 4

Research Summary

AI-generated summary

Updated

Nuvalent (NUVL) CFO Alexandra Balcom Sells Shares, Exercises Options

What Happened
Alexandra Balcom, CFO of Nuvalent, exercised 11,430 option-based shares on March 24, 2026 (exercise price $1.08; cost $12,344) and sold a total of 25,130 shares in open-market transactions on March 24–25, 2026, generating approximately $2.47 million in gross proceeds. The filing shows the 11,430 exercised shares were also recorded as disposed at $0.00 as part of the same reporting entry (see Key Details for notes).

Key Details

  • Primary dates: March 24–25, 2026. Form 4 filed March 26, 2026.
  • Sales (open market): 2,599 shares @ weighted avg $95.03 = $246,983; 7,671 shares @ weighted avg $95.88 = $735,495; 1,160 shares @ weighted avg $96.50 = $111,940; 13,700 shares @ weighted avg $100.16 = $1,372,192. Total sales proceeds ≈ $2,466,610.
  • Option exercise: 11,430 shares acquired at $1.08 per share (total cost $12,344). The same 11,430 shares also appear as disposed at $0.00 in the filing (reported as a derivative disposition).
  • Footnotes: Transactions were effected under a Rule 10b5-1 trading plan adopted Dec 23, 2025 (F1). Reported sale prices are weighted averages across multiple trades with price ranges: $94.34–95.33 (F2), $95.35–96.34 (F3), $96.35–96.72 (F4), $100.00–100.61 (F5). The exercised options are fully vested (F6).
  • Shares owned after the transactions: not specified in the provided filing data.
  • Timeliness: Form 4 was filed March 26, 2026 covering trades on March 24–25; filing was submitted within the typical two-business-day window.

Context
The filing shows an exercise of vested options followed by open-market sales executed under a pre-established 10b5-1 plan. The notation of the exercised shares as disposed at $0.00 likely reflects internal option-settlement or reporting mechanics rather than an open-market sale of those particular shares; the cash proceeds reported come from the separate open-market sales lines. These are routine insider transactions (sales under a trading plan) and are factual disclosures of holdings and transactions rather than statements of intent or company outlook.